Debra Madden

An interview with geneticist and pathologist Gabriel Bien-Willner, MD, PhD, FCAP, on why we need to change our outlook toward precision medicine in oncology.

Why this patient advocate is concerned about the newly proposed Medicare Part B model regarding its level of transparency and the evidence.

Why this patient advocate is concerned about the newly proposed Medicare Part B model regarding its level of transparency and the evidence.

Why this patient advocate is concerned about the newly proposed Medicare Part B model regarding its level of transparency and the evidence.

It is imperative that we gather more mature data on a much larger number of patients to accurately assess efficacy, safety, potential harms, durability of response, and impact on disease progression and overall survival of the new immunotherapy treatments.

It is imperative that we gather more mature data on a much larger number of patients to accurately assess efficacy, safety, potential harms, durability of response, and impact on disease progression and overall survival of the new immunotherapy treatments.

My visit to the gynecologist's office following treatment for breast cancer and a subsequent reconstructive surgery was a rude awakening.

My visit to the gynecologist's office following treatment for breast cancer and a subsequent reconstructive surgery was a rude awakening.

In part 1 of "First Do No Harm," Ms Madden noted important new research suggesting that the majority of patients with HER2+ breast cancer who are treated with the anti-HER2 agent trastuzumab do not receive sufficient cardiac monitoring. In part 2, she discusses the implications of this recent study for patients with this aggressive form of breast cancer and protective strategies against preventable harms of their treatment.

With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.